THE GAP BETWEEN GUIDELINES AND PRACTICE: THE NEED TO DE-ESCALATE INTENSITY OF TREATMENT FOR DIFFERENTIATED THYROID CANCER.

IF 0.8 4区 医学 Q4 ENDOCRINOLOGY & METABOLISM
Acta Endocrinologica-Bucharest Pub Date : 2024-10-01 Epub Date: 2025-10-03 DOI:10.4183/aeb.2024.501
R Mihai, I Cetinoglu, S Roman, J A Sosa
{"title":"THE GAP BETWEEN GUIDELINES AND PRACTICE: THE NEED TO DE-ESCALATE INTENSITY OF TREATMENT FOR DIFFERENTIATED THYROID CANCER.","authors":"R Mihai, I Cetinoglu, S Roman, J A Sosa","doi":"10.4183/aeb.2024.501","DOIUrl":null,"url":null,"abstract":"<p><p>Differentiated thyroid cancer (DTC) generally has an excellent prognosis, yet treatment strategies have traditionally been aggressive, often involving total thyroidectomy followed by radioactive iodine (RAI) ablation and long-term suppressive levothyroxine therapy even in cases considered to be low- or intermediate-risk. In recent years, several guidelines have recommended a more individualized, risk-based approach aiming for a more conservative treatment plan. Despite this paradigm shift, there is a gap between recommendations and actual clinical practice as many centers continue to advocate the more aggressive treatment model. De-escalating the care of selected patients with thyroid cancer include the avoidance of surgery in tumours < 10 mm, the recommendation for thyroid lobectomy for tumours < 4cm, the avoidance of prophylactic lymph node dissection. Evidence based studies show that such strategies do not worsen long-term outcomes, can reduce complications and can lead to better quality of life. Such studies will be summarised in this editorial with the aim of encouraging clinicians to reconsider established treatment protocols and empowering patients to make informed decisions for their care.</p>","PeriodicalId":50902,"journal":{"name":"Acta Endocrinologica-Bucharest","volume":"20 4","pages":"501-507"},"PeriodicalIF":0.8000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12506875/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Endocrinologica-Bucharest","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4183/aeb.2024.501","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/10/3 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Differentiated thyroid cancer (DTC) generally has an excellent prognosis, yet treatment strategies have traditionally been aggressive, often involving total thyroidectomy followed by radioactive iodine (RAI) ablation and long-term suppressive levothyroxine therapy even in cases considered to be low- or intermediate-risk. In recent years, several guidelines have recommended a more individualized, risk-based approach aiming for a more conservative treatment plan. Despite this paradigm shift, there is a gap between recommendations and actual clinical practice as many centers continue to advocate the more aggressive treatment model. De-escalating the care of selected patients with thyroid cancer include the avoidance of surgery in tumours < 10 mm, the recommendation for thyroid lobectomy for tumours < 4cm, the avoidance of prophylactic lymph node dissection. Evidence based studies show that such strategies do not worsen long-term outcomes, can reduce complications and can lead to better quality of life. Such studies will be summarised in this editorial with the aim of encouraging clinicians to reconsider established treatment protocols and empowering patients to make informed decisions for their care.

指南与实践之间的差距:分化型甲状腺癌治疗强度需要降低。
分化型甲状腺癌(DTC)通常预后良好,但治疗策略传统上是积极的,通常包括全甲状腺切除术,放射性碘(RAI)消融和长期左甲状腺素抑制治疗,即使在被认为是低或中等风险的病例中也是如此。近年来,一些指南推荐了一种更个性化的、基于风险的方法,旨在采取更保守的治疗方案。尽管有这种模式的转变,但在建议和实际临床实践之间存在差距,因为许多中心继续提倡更积极的治疗模式。对选定的甲状腺癌患者的降格治疗包括肿瘤< 10mm避免手术,肿瘤< 4cm推荐甲状腺小叶切除术,避免预防性淋巴结清扫。基于证据的研究表明,这种策略不会恶化长期结果,可以减少并发症,并可以提高生活质量。这些研究将在这篇社论中进行总结,目的是鼓励临床医生重新考虑既定的治疗方案,并使患者能够为他们的护理做出明智的决定。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Acta Endocrinologica-Bucharest
Acta Endocrinologica-Bucharest 医学-内分泌学与代谢
CiteScore
1.30
自引率
20.00%
发文量
53
审稿时长
6-12 weeks
期刊介绍: Acta Endocrinologica (Buc) is an international journal covering the fields of basic and clinical Endocrinology, Neuroendocrinology, Reproductive Medicine, Chronobiology, Human Ethology published quarterly Acta Endocrinologica (Buc) is the official international journal of the Romanian Society for Endocrinology. It continues the former Romanian Journal of Endocrinology
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书